Phadia Acquires Nanjing Wei Kang Le Trade Co., (WKL) in China

By Phadia, PRNE
Sunday, December 12, 2010

UPPSALA, Sweden, December 13, 2010 - Phadia today announced that it has entered into an agreement to acquire
100 per cent of the shares in the Chinese marketing company WKL from the
parent company MeiRui. The acquisition is made through AllergonAB, a wholly
owned subsidiary of Phadia, and is subject to approval by Chinese

(Logo: )

Nanjing-based WKL has successfully been marketing and distributing Phadia
products including ImmunoCAP in China for 10 years. WKL has over 50 employees
and more than 100 hospital customers in China's major cities.

The Chinese operations are among the fastest growing areas within Phadia.
The prevalence of allergy is increasing and 30 percent of all children are
expected to develop some form of allergy in the future.

"The acquisition is strategically important for Phadia. It will further
improve diagnosis and management of allergies and provide a strong platform
for accelerated growth," saysJean Forcione, Chief Operating Officer,

Completion of the transaction is expected by the end of 2010, and is
subject to regulatory approval.

About Phadia

PhadiaAB is a global leader in allergy, asthma and autoimmunity
diagnostics. Phadia develops, manufactures and markets complete blood test
systems to support clinical diagnosis and management. Phadia has marketing
companies in more than 20 countries and distributors in about 60 countries.
Phadia is owned by the leading European buyout firm Cinven. For more
information please visit

    Media Contact:

    Ulf Bladin
    VP Marketing, Corporate Communication, Scientific Affairs
    Tel. +46-73-800-24-88


Media Contact: Ulf Bladin, VP Marketing, Corporate Communication, Scientific Affairs, Tel. +46-73-800-24-88, ulf.bladin at

will not be displayed